BCLC Staging for Hepatocellular Carcinoma
Barcelona Clinic Liver Cancer (BCLC) staging system — the most widely used HCC staging and treatment allocation tool, endorsed by EASL and AASLD.
Score interpretation
BCLC Stage 0: Single nodule ≤ 2 cm, Child-Pugh A, PS 0. Excellent prognosis (5-year survival > 70%).
→ Resection is first-line if technically feasible (non-cirrhotic or portal hypertension absent). Liver transplant if meets Milan criteria and resection not possible. Ablation (RFA/MWA) for non-surgical candidates. Enrol in HCC surveillance programme.
BCLC Stage A: single nodule, or 2–3 nodules each ≤ 3 cm; Child-Pugh A–B; PS 0. Potentially curative.
→ Resection (single tumour, no portal hypertension, adequate remnant liver). Liver transplant (Milan criteria — single ≤ 5 cm or ≤ 3 nodules ≤ 3 cm). Ablation if not surgical candidate. TACE if ablation not possible. MDT decision.
BCLC Stage B: Multinodular beyond Milan, no vascular invasion/mets, Child-Pugh A–B, PS 0. Median survival ~20 months.
→ Trans-arterial chemoembolisation (TACE) — first-line. Consider TARE (Y-90 radioembolisation) if suitable. Systemic therapy if TACE contraindicated. Reassess for downstaging to transplant criteria.
BCLC Stage C: portal invasion or extrahepatic spread, and/or ECOG PS 1–2; Child-Pugh A–B. Median survival ~12 months.
→ Systemic therapy: atezolizumab + bevacizumab (first-line, IMBRAVE150). Alternative: sorafenib or lenvatinib. Clinical trial enrolment. Palliative care parallel planning. Child-Pugh C: best supportive care only.
BCLC Stage D: Child-Pugh C or PS 3–4. End-stage disease. Median survival < 3 months.
→ Best supportive care. Palliative and symptom management. Comfort-focused approach. Multidisciplinary palliative care referral. Advance care planning.
Interpretation bands for the BCLC Staging. Apply clinical judgement and local guidance.
References
- Reig M et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022.
- EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. J Hepatol. 2018.
Related
Curated clinical cross-links plus same-class fallbacks.
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.